UP - logo
E-viri
Celotno besedilo
Recenzirano
  • Sachdev, Sean; Dmello, Crismita; Sonabend, Adam M

    Clinical cancer research, 05/2023, Letnik: 29, Številka: 9
    Journal Article

    Isocitrate dehydrogenase 1-mutant (IDH1m) gliomas are recalcitrant tumors for which radiotherapy remains a standard treatment. A recent study identified ZMYND8 as a key mediator of radioresistance for IDH1m gliomas, and pharmacologic targeting of this pathway may heighten radiotherapy-induced tumor response, providing a prospect of improved clinical outcomes. See related article by Carney et al., p. 1763.